TrialPath
Recruiting

Project STRONGER: Stepped Care for Opioid Use Disorder Treatment Engagement and Recovery

NCT07115030 · Yale University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Using a hybrid type 1 effectiveness-implementation approach, this study aims to evaluate the impact of a novel stepped care model ("PCT+2HOPE") versus treatment as usual (TAU) on increasing retention in community-based medication for opioid use disorder (MOUD) treatment among women who have experienced intimate partner violence (W-IPV). PCT+2HOPE includes Present-Centered Therapy (PCT+) with stepped care as indicated by moderate, severe, or extreme PTSD-related impairment in psychosocial functioning to Helping to Overcome PTSD through Empowerment (HOPE), two evidence-based behavioral interventions adapted for women with opioid use disorder (OUD). We will examine the effectiveness of PCT+2HOPE vs. TAU on the primary outcome (i.e., retention in MOUD treatment) and secondary outcomes related to trauma (i.e., PTSD-related impairment in psychosocial functioning and depression), substance use (i.e. OUD symptom severity, extra-medical opioid use \[i.e., use of prescription opioids without a doctor's prescription; in greater amounts, more often, longer than prescribed, or for a reason other than a doctor said they should be used\], and recovery), and empowerment. We will explore the extent to which the effectiveness of PCT+2HOPE vs. treatment as usual differs based on access to basic needs. We will also conduct an implementation-focused process evaluation.
Eligibility criteria
Inclusion Criteria: * Woman; * Are ≥ 18 years old; * Receive MOUD treatment at one of the participating sites; * Have received MOUD for \>14 days to allow for initial stabilization; * Have initiated the current treatment episode within the past 12 months; * Experienced physical or psychological IPV in their lifetime; * Have at least moderate impairment in psychosocial functioning (on B-IPF) as a result of PTSD symptoms; * Available during the date/time of the intervention group * Able to read/understand English; and * Provide written informed consent. Exclusion Criteria: * Fail a capacity-to-consent questionnaire; * Have an unstable medical condition (e.g., hospitalization, planned surgery, newly starting chemotherapy, plans for palliative care) and/or unstable psychiatric illness (e.g., untreated psychosis) that would interfere with their ability to participate in study activities; * Will be unavailable for \>4 consecutive weeks during the study period (e.g., anticipated move, planned surgery); * Are unable to read/understand English; * Inability to provide at least one form of contact
Study design
Enrollment target: 532 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-06-01
Estimated completion: 2029-08-31
Last updated: 2026-07-16
Interventions
Behavioral: PCT+2HOPE
Primary outcomes
  • • Retention in MOUD treatment (Week 26)
Sponsor
Yale University · other
With: National Institute on Drug Abuse (NIDA)
Contacts & investigators
ContactTami Sullivan, PhD · contact · tami.sullivan@yale.edu · 203-789-7645
ContactAshley Clayton, MA · contact · ashley.clayton@yale.edu · 203-789-7645 ext 121
InvestigatorTami Sullivan, PhD · principal_investigator, Yale University
InvestigatorE. Jennifer Edelman, MD, MHS, AAHIVS · principal_investigator, Yale University
InvestigatorDawn Johnson, PhD · principal_investigator, The University of Akron
All locations (3)
Liberation ProgramsRecruiting
Bridgeport, Connecticut, United States
Community Health Resources (CHR) Pathways Opiate Treatment ProgramNot Yet Recruiting
Enfield, Connecticut, United States
The APT Foundation, Inc.Recruiting
West Haven, Connecticut, United States